Free Newsletter
New therapy found for schizophrenia
There are a wide range of cognitive disorders associated with schizophrenia: poor memory, impaired attention, difficulty with problem-solving. And the current class of drugs used to treat the hallucinations and delusions associated with schizophrenia have only a limited success with these cognitive disorders. But scientists at the Institute for Neurodegenerative Disorders report that they have identified a drug that has "a normalizing effect on the spontaneous activity of prefrontal cortex neurons." The therapy reverses chemically induced abnormalities in prefrontal cortical functioning. Researcher Bita Moghaddam says that their work can lead the way to the development of new therapies that are specifically targeted at these cognitive disorders.
- see this release
Related Articles:
Lilly's schizophrenia drug may offer breakthrough. Report
New schizophrenia drugs little better than the old. Report
Mice engineer to be schizophrenic. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




